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Few peptide hormones have attracted as much attention of
the scientiﬁc community as ghrelin, the natural secretagogue
for growth hormone (GH) identiﬁed by M. Kojima et al.
in 1999 [1], resulting in more than 4000 PubMed citations
over the last ten years. The initial interest can be attributed
to the ability of ghrelin to stimulate feeding in mammals,
suggesting it as a potential target for the development
of antiobesity drugs. Many studies investigating this issue
have however revealed the complexity of the ghrelin system
including the diﬀerential physiological eﬀects of the three
peptide products of the ghrelin gene: ghrelin, which is peri-
translationally modiﬁed via acylation with the octanoic acid;
des-acyl ghrelin that is not acylated or has lost its fatty acid
residue; and obestatin, another bioactive peptide derived
from the preproghrelin precursor. Most importantly, it has
been realized that beside stimulation of GH secretion and
increased feeding, ghrelin has multiple biological eﬀects that
would be important to preserve if aiming to antagonize
ghrelin-mediated positive energy balance. Among these
functions, ghrelin was found to regulate gastrointestinal
motility and associated sensory functions, to modulate the
reproductive and stress axes, mood and emotion, glucose
metabolism, as well as aﬀecting the cardiovascular system
and renal function.
The present special issue “Update on ghrelin” includes
nineteen reviews and one original study and starts with the
review by J. D. Veldhuis and C. Y. Bowers who “integrate the
GH axis into the ghrelin system” and discuss the biological
background of the multiplicity of ghrelin’s functions with
their relevance to drug development [2]. Other articles, as
introduced below, provide in more details some speciﬁc
aspects of the ghrelin system, altogether providing a com-
prehensive overview of the current knowledge in the ﬁeld
and showing how ghrelin research has helped advance our
understanding of both physiology and disease.
Ghrelin is abundantly synthesized by specialized mucosal
cells in the stomach accounting for about 80% of the serum
ghrelin production in rats and for 65% in humans. Some
ghrelin producing cells are also found in lower parts of the
gastrointestinal (GI) tract, where ghrelin expression can be
increased, for example, after gastrectomy [3]. Interestingly,
gastric ghrelin cells are of the closed type, whereas those
in the lower GI tract are of both the closed and the open
type, suggesting their regulation preferentially by hormonal
or luminal factors, respectively. These cellular and also
phylogenic and ontogenic aspects of ghrelin production in
the GI tract are reviewed by I. Sakata and T. Sakai [4].
Moreover, Fujimiya and colleagues show that the closed type
gastric cells contain ghrelin, des acyl-ghrelin, and obestatin,
while the open type cells contain only des-acyl ghrelin
supportingaroleofluminalpHondes-acylghrelinsecretion
[5].
Although the role of ghrelin to stimulate feeding is
evident in mammals, it is possible that this function of
ghrelin is evolutionary late and redundant, and that ghrelin
has evolved as a messenger mediating other vital functions
such as activation of the somatotropic axis. In fact, in ﬁsh,
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of ghrelin is an inconsistent ﬁnding and can be species
dependent while the GH stimulating eﬀect is preserved [6].
This phenomenon is even more evident in birds, where ghre-
lin stimulates GH secretion and the hypothalamo-pituitary
adrenal stress axis but inhibits feeding and drinking. The
avian ghrelin system is discussed in details in the review by
M. P. Richards and J. P. McMurtry [7].
The integrative role of ghrelin in homeostatic regulation
is evident from its function in the regulation of repro-
duction versus feeding. Ghrelin inhibits the activity of the
hypothalamo-pituitary-gonadal axis acting both centrally
and peripherally, similar to hypothalamic neuropeptide
Y (NPY), a down-stream target of ghrelin. In addition,
ghrelin also acts directly to inhibit reproductive function
during conditions of energy deﬁcit. The eﬀects of ghrelin in
modulation of the activity of the gonadal axis in both males
and females are reviewed by J. Dupont et al. [8].
Although ghrelin stimulates feeding, it inhibits drinking
and activates neurons of the hypothalamic subfornical
organ usually associated with dehydration. This suggests
that circulating ghrelin may signal to the brain via the
circumventricular organs not necessarily associated with the
median eminence. However, how peripheral ghrelin enters
the brains is still an unresolved issue discussed in details by
M. Fry and A. V. Ferguson who propose the relaying roles of
the circumventricular organs such as the subfornical organ
a n da r e ap o s t r e m a[ 9].
Initsroleinfoodintakeregulation,ghrelininteractswith
gastrointestinal hormones signaling satiety such as chole-
cystokinin, bombesin, peptide YY, glucagon-like peptide,
pancreatic polypeptide, and amylin. As discussed by A. S.
Wisser et al., these peptides may inhibit ghrelin secretion or
antagonizeitsactionintheappetiteregulatoryneuronsinthe
brain [10]. Since plasma levels of ghrelin normally fall after a
meal, it is possible to use it as a satiety marker to evaluate the
satietogenic properties of diﬀerent macronutrients for the
development of various nutritional antiobesity approaches.
How diﬀerent types of nutrients aﬀect ghrelin secretion is
reviewed by C. Koliaki et al. [11].
In addition to the appetite-related neuronal pathways
activated by ghrelin, ghrelin receptors are present in many
brain areas that can aﬀect mood and emotion, and, indeed,
it was found that ghrelin may interfere with the regulation
of the stress response, mood, and anxiety. Again, in analogy
to the orexigenic NPY, which also regulates these behavioral
modalities, the situation with ghrelin is not simple, and both
anxiolytic and anxiogenic eﬀects have been attributed to
ghrelin as discussed by J. C. Chuang and J. M. Zigman [12].
Further elucidation of the brain ghrelin system should help
to clarify the role of ghrelin, which will be important for the
designing of drugs targeting the ghrelin system.
Next, ﬁve reviews provide full coverage of the important
role of ghrelin in inﬂuencing gastrointestinal contractility
and motility in normal and pathological conditions, as well
as showing its relevance to both new and old therapeutic
approaches. H. S. Sallam and J. D. Z. Chen introduce the
subject with a meticulous review of the experimental and
clinical data accumulated during the last ten years related
to ghrelin’s prokinetic eﬀects [13]. T. Ohno et al. discuss the
possibility that changes of plasma ghrelin concentration are
not relevant to the prokinetic eﬀect of ghrelin because of
the decreased plasma levels found after a meal, similar to
the situation observed for motilin, a hormone structurally
related to ghrelin [14]. Further, the complexity of the ghrelin
system in inﬂuencing gastric motility is presented in the
review by M. Fujimiya et al. who discuss the diﬀerential
eﬀects of ghrelin, des-acyl ghrelin, and obestatin, providing
evidence for the implication of distinct central pathways
in these eﬀects involving hypothalamic NPY, corticotropin-
releasing hormone, and urocortin [5]. As gastric motility
is altered in subjects with functional dyspepsia who also
experience abdominal discomfort, nausea, and decreased
appetite, exploring a role of ghrelin in these patients may be
worthwhile.Indeed,asdiscussedbyT.Akamizuetal.,plasma
levels of ghrelin have been found to correlate with reduction
of symptoms in these patients and excitedly, a preliminary
study using synthetic ghrelin showed a therapeutic potential
infunctionaldyspepsia[15].Thus,ghrelinoritsanalogsmay
become new drugs for the treatment of functional dyspepsia.
Similarly,improvementinphysiologicalghrelinsecretion
may underlie the beneﬁcial eﬀects of other therapeutic
approaches, for example, traditional medicine. Such an
example is given in the review by T. Hattori who discusses
the mechanisms behind the beneﬁcial eﬀects of Rikkunshito,
a traditional Japanese medicine based on a mixture of
eight herbs. In fact, Rikkunshito was shown to alleviate
dyspepsia, for example, during cancer chemotherapy, and
this improvement was associated with increased ghrelin
secretion [16].
Ghrelin is also expressed in the pancreatic islets and
has an intricate relation with insulin in regulation of the
glucose metabolism. These eﬀects of ghrelin with relation
to the pathophysiology of type 2 diabetes are reviewed in
great detail by S. Sangiao-Alvarellos and F. Cordido [17].
The authors also discuss the results obtained in ghrelin- and
ghrelin receptor-knockout mice, suggesting that absence of
ghrelin signaling is more relevant to glucose homeostasis
thantofoodintakecontrol,supportingthephylogeneticdata
mentioned above.
Interestingly, although ghrelin stimulates feeding, low
plasma levels of ghrelin are commonly present in obesity
w h e r e a sl e v e l su s u a l l yi n c r e a s ew i t hw e i g h tl o s s .T h e s ed a t a
do not support the causative role of ghrelin in increased
appetite in obesity but may suggest a link via the role
of ghrelin in glucose homeostasis. L. Pulkkinen et al. in
their review make an emphasis on the relation between
ghrelin and insulin resistance and human genetics in the
development of obesity and the metabolic syndrome [18].
Further data of the putative role of ghrelin in obesity
come from studies of obese subjects who have undergone
bariatric surgery and hence have reduced gastric ghrelin
production. As reviewed by D. J. Pournaras and C. W. le
Roux [19], ghrelin plasma levels are altered after the surgery,
and both decreased and increased levels were documented.
In addition, similar results have also been reported in rats
[3]. As bariatric surgery is accompanied by reduced appetite
and body weight, the serum ghrelin data do not support a
causative role of ghrelin in these beneﬁcial eﬀects. However,International Journal of Peptides 3
bariatric surgery is consistently associated with an improved
insulin resistance and diabetes, taken by some as a reason
to rename the surgery “metabolic” and pointing to that the
surgery-associated changes of ghrelin serum levels might still
have beneﬁcial eﬀects on the glucose metabolism.
Expression of ghrelin and the ghrelin receptor was found
in vascular endothelial cells providing the background for
the vascular eﬀects of ghrelin. In fact, ghrelin was shown
to decrease blood pressure, although this eﬀect might also
involve the modulation of the central sympathetic tone. The
cardiovascular eﬀects of ghrelin are discussed by M. Tesauro
et al. showing that activation of the ghrelin system might
be a new therapeutic approach for chronic heart failure and
cardiaccachexia[20].A.Lavianoetal.reviewtherelevanceof
ghrelin in another form of cachexia associated with chronic
renal failure both in regard to its pathophysiology and to
its putative therapeutic role [21]. The authors propose the
use of exogenous ghrelin which should be able to overcome
endogenous ghrelin resistance present in renal cachexia, that
might improve the nutritional status in cachectic patients. In
fact,syntheticghrelinorghrelinanalogsmightbeconsidered
as a new therapy for a variety of pathological conditions
characterized by anorexia or cachexia. For instance, a state
of ghrelin resistance is present in anorexia nervosa, and a
recent pilot study showed that administration of ghrelin is
accompanied by improved appetite in these patients [22].
Another possible indication of “ghrelin therapy” can be
anorexia associated with gastrectomy as suggested by the
experimental study in Yada’s laboratory [3].
To conclude this editorial, ten years of ghrelin research
indicate that this peptide initially identiﬁed as a GH secret-
agogue is an universal hormone. As guest editors, we thank
all the authors who have contributed to this special issue for
preparing excellent articles and we wish the readers a good
time in exploring the ghrelin world, which we ﬁnd ourselves
most exciting and promising for the new discoveries and
potential therapeutic spin oﬀs.
Sergue¨ ıO .F e t i s s o v
Alessandro Laviano
Satya Kalra
Akio Inui
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